Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon α-2b + arsenic trioxide + venetoclax
- Development stage
- Unknown
- Lead developer
- Zhejiang Provincial People's Hospital
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
This combination therapy, consisting of interferon α-2b, arsenic trioxide (ATO), and venetoclax, is being investigated by Zhejiang Provincial People's Hospital for the treatment of arsenic-resistant relapsed acute promyelocytic leukemia (APL). Interferon α-2b is a recombinant Type I interferon that exerts antiproliferative and immunomodulatory effects by binding to specific cell-surface receptors. Arsenic trioxide is a mainstay of APL treatment that induces the degradation of the PML-RARA fusion protein, leading to cell differentiation and apoptosis. Venetoclax is a potent, selective oral B-cell lymphoma 2 (BCL-2) inhibitor that restores the apoptotic process in cancer cells. This triplet regimen is designed to overcome therapeutic resistance in patients who have failed standard arsenic-based induction and consolidation therapies.
- Other names
- Interferon-α combined with ATO and Venetoclaxinterferon α-2b + arsenic trioxide + venetoclax
02
Targets
BCL-2 (BCL-2 family)IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)PML-RARA (PML-retinoic acid receptor alpha fusion protein)IFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on interferon α-2b + arsenic trioxide + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon α-2b + arsenic trioxide + venetoclax.